Biodol Therapeutics: Funding, Investors & Team (Sep 2026)
Established in 2015, Biodol Therapeutics focuses on creating innovative compounds to treat chronic pain. The company has pinpointed the Receptor Tyrosine Kinase (RTK) FLT3 as a crucial factor in both triggering and sustaining chronic neuropathic pain. Recent research conducted in collaboration with the INSERM Institute for Neurosciences in Montpellier uncovered that inhibiting FLT3 can enhance the effectiveness of opioids in pain relief, while also decreasing potential risks such as addiction. Biodol Therapeutics' development of extracellular inhibitors for the FLT3 receptor is a unique and essential strategy in their work.
Biodol Therapeutics has raised $7.6M across 1 funding round on record, the most recent an undisclosed round of $7.6M announced in May 2024.
That round is above the $4.7M median round size for Health Care companies tracked on FundedIQ over the last two years.
Biodol Therapeutics Company Profile and Key Stats
Latest funding round on record: May 2024.
Biodol Therapeutics Funding Rounds
Biodol Therapeutics Founders and Leadership Team
Contact details for the Biodol Therapeutics team: 1 of 1 has an email address on file.
Start 14-day free trial →Biodol Therapeutics Funding Compared to Other Health Care Startups
Biodol Therapeutics' latest round of $7.6M is above the median round in Health Care. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Biodol Therapeutics in Health Care and Clapiers
Companies Similar to Biodol Therapeutics
Beams is a producer of medical devices for cancerology based on the use of particles β.
Padoa is an occupational health software firm that develops a tool for monitoring the health of employees.…
CILcare specializes in providing drug solutions for hearing and ear disorders.
MEDIAN Technologies develops medical imaging software and services dedicated to oncology clinical trials,…
noa is a digital fitness and wellness company that offers premium, structured training programs for strength,…
Semeia offers patient monitoring solution designed to support medical followup of patients, remotely and in…
Signadori Bio is the next-generation cellular immunotherapy for cancer cure.This has culminated in the…
Axomove is an e-wellbeing application that spends significant time in video actual activities.
Parallel helps coding agent works side by side with hospital teams to deliver faster and more accurate…
May Health has created a new solution for infertility caused by Polycystic Ovary Syndrome (PCOS) that is…
MedinCell is an injectable slow-release drug specialist company.
Charles helps men regain control over their daily health concerns by starting with their personal health.
Biodol Therapeutics Funding FAQs
What does Biodol Therapeutics do?
Established in 2015, Biodol Therapeutics focuses on creating innovative compounds to treat chronic pain. The company has pinpointed the Receptor Tyrosine Kinase (RTK) FLT3 as a crucial factor in both triggering and sustaining chronic neuropathic pain. Recent research conducted in collaboration with the INSERM Institute for Neurosciences in Montpellier uncovered that inhibiting FLT3 can enhance the effectiveness of opioids in pain relief, while also decreasing potential risks such as addiction. Biodol Therapeutics' development of extracellular inhibitors for the FLT3 receptor is a unique and essential strategy in their work.
How much funding has Biodol Therapeutics raised?
Biodol Therapeutics has raised $7.6M across 1 round on record. The most recent is an undisclosed round of $7.6M announced in May 2024.
When did Biodol Therapeutics last raise funding?
Biodol Therapeutics' most recent funding round on record is an undisclosed round of $7.6M, announced in May 2024.
Who founded Biodol Therapeutics?
FundedIQ lists Fabien Granier (Founder) at Biodol Therapeutics.
Where is Biodol Therapeutics headquartered?
Biodol Therapeutics is based in Clapiers, Languedoc-Roussillon, France.
How many employees does Biodol Therapeutics have?
Biodol Therapeutics is in the 11-50 employee band.
How does Biodol Therapeutics' funding compare to other Health Care startups?
Biodol Therapeutics' latest round of $7.6M is above the $4.7M median round size for Health Care companies on FundedIQ across 3,653 tracked companies over the last two years.
About FundedIQ's Biodol Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Biodol Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.